Related Experiment Videos
[The antiandrogen withdrawal syndrome: decrease in prostate specific antigen serum levels after withdrawal of
M Hornák1, A Bárdos, F Goncalves
1Urologická klinika LF UKo, Bratislava, Slovenská republika.
Rozhledy V Chirurgii : Mesicnik Ceskoslovenske Chirurgicke Spolecnosti
|February 21, 1998
Summary
For metastatic prostate cancer patients progressing on combined androgen blockade, withdrawing anti-androgen therapy can lead to a PSA decline. This anti-androgen withdrawal offers a temporary response in some patients.
Area of Science:
- Oncology
- Urology
Context:
- Metastatic prostate cancer is primarily treated with combined androgen blockade (CAB).
- Progression on CAB typically occurs within 18-30 months.
- Anti-androgen withdrawal is a strategy explored upon progression.
Purpose:
- To investigate the effect of non-steroid anti-androgen withdrawal in patients with metastatic prostate cancer progressing on CAB.
Summary:
- In a study of 35 patients with metastatic prostate cancer progressing on CAB, flutamide withdrawal was assessed.
- A prostate-specific antigen (PSA) decline was observed in 22.9% of patients following flutamide withdrawal.
- The mean time to progression on CAB was 26 months, with a mean response duration to flutamide withdrawal of 4.1 months.
Impact:
- Anti-androgen withdrawal can induce a temporary PSA response in a subset of patients with advanced prostate cancer.
- This finding suggests a potential therapeutic window upon progression of metastatic prostate cancer.
- Further research is warranted to optimize this strategy and understand its mechanisms.